Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock

Study to see if weight loss drugs change biological age

NCT: NCT07444073 · Status: NOT YET RECRUITING · Phase: N/A · Sponsor: National University of Singapore · Started: 2026-02-02 · Est. Completion: 2026-12-31

Plain English Summary

Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock is a Not Applicable clinical trial sponsored by National University of Singapore studying Aging, Obesity & Overweight. This study will look at how weight loss medications, like semaglutide and tirzepatide, affect biological aging in people trying to lose weight. It is for adults aged 40-89 who are overweight or obese and joining a specific weight management program. Participants will have their biological age measured at the start and after 6 months, as part of their regular weight loss program. There are no alternative treatments being tested in this study; it observes current medical practices. The trial aims to enroll 440 participants.

Official Summary

This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.

Who Can Participate

Here is what you need to know about eligibility for this trial. You can join if you are between 40 and 89 years old and are starting a new weight management program. You need to have a BMI of 27.5 or higher (if Asian) or 30 or higher (if non-Asian), or a lower BMI if you have a weight-related health condition. You cannot join if you are pregnant or breastfeeding, have certain cognitive or psychiatric conditions, are undergoing cancer treatment, or have had a bad reaction to similar medications. This trial is studying Aging, Obesity & Overweight, so participants generally need a confirmed diagnosis.

What They're Measuring

The primary outcome measures how 'old' your body is biologically, using a special test called LinAge2, to see if the weight loss program makes you biologically younger over 6 months. The specific primary outcome measures are: LinAge2 Biological Age (Baseline and 6 months). These endpoints are how researchers determine whether the treatment is effective and will form the basis of any future regulatory submissions.

About This Phase

This study does not have a traditional clinical phase designation. It may be an observational study that follows patients without intervening in their care, an expanded access or compassionate use program, or other non-interventional research. These studies contribute valuable data about disease progression, treatment patterns, and patient outcomes.

Why This Trial Matters

This trial matters because it could show if common weight loss treatments can actually make people biologically younger, addressing a gap in understanding the long-term health benefits of these medica This research targets Aging, Obesity & Overweight, where improved treatment options are needed.

Investor Insight

This observational study signals interest in the growing market for weight loss drugs and aging biomarkers, with potential implications for future drug development and healthspan research.

Is This Trial Right for Me?

Ask your doctor if this study aligns with your weight loss goals and if the medications used are appropriate for you. Participation involves standard medical assessments and measurements as part of your regular weight management program, with no extra procedures required for the study itself. You will have your biological age assessed at the beginning and after six months of the program. The trial is being conducted at 2 sites. Always discuss clinical trial participation with your healthcare provider before making any decisions. This information is for educational purposes only and is not medical advice.

AI-generated analysis for educational purposes only. This is not medical advice. Discuss clinical trial participation with your doctor. Data sourced from ClinicalTrials.gov.

Study Design

Interventions

Primary Outcomes

Secondary Outcomes

Full Eligibility Criteria

Inclusion Criteria:

* Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program.
* BMI of ≥ 27.5 kg/m2 (if Asian) or 30 kg/m2 (if non-Asian); OR
* BMI of ≥ 23 kg/m2 (if Asian) / 25 (if non-Asian) kg/m2 in the presence of a weight-related chronic condition (e.g., diabetes, pre-diabetes, polycystic ovarian syndrome, hypertension, fatty liver, high cholesterol).

Exclusion Criteria:

* Pregnancy or lactation.
* Non-ambulatory status, total blindness, complete hearing loss, or inability to speak.
* Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes.
* Concomitant anti-diabetic therapy.
* Active cancer on chemotherapy or immunotherapy.
* Known hypersensitivity or contraindications to GLP-1 RAs.
* Any condition, in the opinion of the attending clinician, that would jeopardize participant safety or interfere with study compliance.

Trial Locations

Frequently Asked Questions

What is clinical trial NCT07444073?

NCT07444073 is a Not Applicable OBSERVATIONAL study titled "Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock." It is currently not yet recruiting and is sponsored by National University of Singapore. The trial targets enrollment of 440 participants.

What conditions does NCT07444073 study?

This trial investigates treatments for Aging, Obesity & Overweight. The primary condition under study is Aging.

What treatments are being tested in NCT07444073?

The interventions being studied include: Not applicable. This is an observational study. (OTHER). Not applicable. This is an observational study.

What does Not Applicable mean for NCT07444073?

This study does not have a defined clinical phase. It may be an observational study, expanded access program, or other non-interventional research.

What is the current status of NCT07444073?

This trial is currently "Not Yet Recruiting." It started on 2026-02-02. The estimated completion date is 2026-12-31.

Who is sponsoring NCT07444073?

NCT07444073 is sponsored by National University of Singapore. The sponsor is responsible for funding, designing, and overseeing the clinical trial.

How many people can participate in NCT07444073?

The trial aims to enroll 440 participants. The trial has not yet started recruiting.

How is NCT07444073 designed?

This is a observational study.

What are the primary outcomes being measured in NCT07444073?

The primary outcome measures are: LinAge2 Biological Age (Baseline and 6 months). These are the main endpoints researchers use to determine whether the treatment is effective.

Where is NCT07444073 being conducted?

This trial is being conducted at 2 sites, including Singapore (Singapore).

Where can I find official information about NCT07444073?

The official record for NCT07444073 is available on ClinicalTrials.gov at https://clinicaltrials.gov/study/NCT07444073. This government database provides the most up-to-date and detailed information about the trial.

What is NCT07444073 testing in simple terms?

This study will look at how weight loss medications, like semaglutide and tirzepatide, affect biological aging in people trying to lose weight. It is for adults aged 40-89 who are overweight or obese and joining a specific weight management program.

Why is this trial significant?

This trial matters because it could show if common weight loss treatments can actually make people biologically younger, addressing a gap in understanding the long-term health benefits of these medica

What are the potential risks of participating in NCT07444073?

Potential side effects of the weight loss medications may include nausea, vomiting, diarrhea, or constipation. Some individuals may experience fatigue or dizziness, and there's a risk of allergic reactions to the medications. The study itself carries minimal risk as it observes standard care, but individual health conditions could be affected by the weight loss program. As with any clinical trial, participants are closely monitored and can withdraw at any time.

Should I consider participating in NCT07444073?

Ask your doctor if this study aligns with your weight loss goals and if the medications used are appropriate for you. Participation involves standard medical assessments and measurements as part of your regular weight management program, with no extra procedures required for the study itself. You will have your biological age assessed at the beginning and after six months of the program. Always discuss clinical trial participation with your healthcare provider to determine if it is appropriate for your specific situation.

What does NCT07444073 signal from an investment perspective?

This observational study signals interest in the growing market for weight loss drugs and aging biomarkers, with potential implications for future drug development and healthspan research. This is a Not Applicable trial, which is in early development stages.

What happens if the treatment in this trial doesn't work?

Participants will have their biological age measured at the start and after 6 months, as part of their regular weight loss program. Participants in clinical trials always have the right to withdraw and pursue alternative treatments. The study team will help transition patients to other available options.

Related Conditions

More Aging Trials

View all Aging clinical trials

This analysis is AI-generated and does not constitute medical advice. Always consult your healthcare provider before making decisions about clinical trial participation.